PFE · 10-Q · 2026Q3 · Full report

Net Income and Profitability

PFIZER INC · 2026-11-03 · Importance 24 · Surprise 14

Income from continuing operations before taxes increased $51 million to $3.4 billion in the third quarter of 2026 from $3.3 billion a year earlier. The quarterly comparison benefited from lower cost of sales and acquired in-process R&D expense, the non-recurrence of a prior-year intangible impairment, and lower legal charges, but was partly offset by higher R&D and restructuring costs and unfavorable equity-security and contingent-consideration movements. For the first nine months, pretax income fell $3.3 billion to $5.9 billion from $9.2 billion. The nine-month decline reflected impairment and legal charges, higher contingent-consideration liabilities, R&D, cost of sales, and restructuring costs, partly offset by a gain on the sale of the prior ViiV investment and higher revenue.

Key facts

• Pfizer's income from continuing operations before taxes decreased $3.3 billion to $5.9 billion in the first nine months of 2026 from $9.2 billion in the first nine months of 2025. source
• For the nine months ended September 27, 2026, Pfizer reported GAAP net income attributable to common shareholders of $5.681 billion and non-GAAP adjusted net income of $13.715 billion. source
• Pfizer's income from continuing operations before taxes increased $51 million to $3.4 billion in Q3 2026 from $3.3 billion in Q3 2025. source
• For the nine months ended September 27, 2026, Pfizer reported diluted GAAP EPS of $0.99 and diluted non-GAAP adjusted EPS of $2.39. source